Abbott Laboratories has reported an increase in nine-month sales from its nutrition division as recently-launched infant formula and Ensure adult nutrition drinks boosted third-quarter revenue.
The maker of Eleva and Similac infant formula saw sales from its nutrition business, excluding foreign exchange, grow 3.7% in the nine months to the end of September. On a reported basis, which includes the impact of exchange rates, sales increased 2.2% to to US$5.15bn.
Go deeper with GlobalData
By segment, Abbott saw infant formula sales inch up 0.8%, excluding currency fluctuation, over the nine months. However, including exchange rates, revenue fell 0.6% to $2.84bn.
The US group’s adult nutrition arm enjoyed faster growth, with sales up 7.7% excluding currency and rising 5.9% to $2.31bn on a reported basis.
Both divisions saw sales accelerate in the third quarter. Looking at the numbers excluding currency, Abbott’s paediatric sales were up 8.6%. The company pointed to the impact of the launches of Eleva and Similac Qinti infant formula in China.
See Also:
The company’s adult nutrition business saw sales climb 11.8%. It cited “strong growth” from the Ensure brand.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataClick here for the full results.
